Permeability Enhancing and Chemotactic Activities of Lower Molecular Weight Degradation Products of Human Fibrinogen

Katsuo Sueishi; Shigeru Nanno; Kenzo Tanaka

doi:10.1055/s-0038-1650136

Thrombosis and Haemostasis, Table of Contents

Thromb Haemost 1981; 45(01): 090-094
DOI: 10.1055/s-0038-1650136

Original Article

Schattauer GmbH Stuttgart

Permeability Enhancing and Chemotactic Activities of Lower Molecular Weight Degradation Products of Human Fibrinogen

Authors

Katsuo Sueishi

The Department of Pathology, Faculty of Medicine, Kyushu University, Fukuoka, Japan
Shigeru Nanno

The Department of Pathology, Faculty of Medicine, Kyushu University, Fukuoka, Japan
Kenzo Tanaka

The Department of Pathology, Faculty of Medicine, Kyushu University, Fukuoka, Japan

Abstract

PDF Download

Summary

Fibrinogen degradation products were investigated for leukocyte chemotactic activity and for enhancement of vascular permeability. Both activities increased progressively with plasmin digestion of fibrinogen. Active fragments were partially purified from 24 hr-plasmin digests. Molecular weights of the permeability increasing and chemotactic activity fractions were 25,000-15,000 and 25,000 respectively. Both fractions had much higher activities than the fragment X, Y, D or E. Electron microscopic observation of the small blood vessels in rabbit skin correlated increased permeability with the formation of characteristic gaps between adjoining endothelial cells and their contraction.

These findings suggest that lower molecular weight degradation products of fibrinogen may be influential in contributing to granulocytic infiltration and enhanced permeability in lesions characterized by deposits of fibrin and/or fibrinogen.

Keywords

Lower molecular weight FDP - Permeability - Chemotactic activity

PDF (1557 kb)

References

References
1 Godal HC, Helle I. The influence of fibrinogenolytic and fibrinolytic split products on the last stage of coagulation. Scand J Clin Lab Invest 1963; 15: 327-338
2 Kowalski E. Fibrinogen derivatives and their biological activities. Semin Hematol 1968; 5: 45-59
3 Marder VJ, Shulman NR. High molecular weight derivatives of human fibrinogen produced by plasmin. II. Mechanism of their anticoagulant activity. J Biol Chem 1969; 244: 2120-2124
4 Mitchell PS, Beller FK. Quantitation of the coagulation inhibition in vivo due to breakdown products of fibrin. Thromb Diath Haemorrh 1970; 23: 477-485
5 Larrieu MJ, Rigollot C, Marder VJ. Comparative effects of fibrinogen degradation fragments D and E on coagulation. Br J Haematol 1972; 22: 719-733
6 Arnesen H. The effect of products D and E on the thrombin induced conversion of fibrinogen to fibrin. Scand J Haematol 1974; 12: 165-172
7 Niewiarowski S, Gurewich V. Laboratory identification of intravascular coagulation. The serial dilution protamine sulfate test for the detection of fibrin monomer and fibrin degradation products. J Lab Clin Med 1971; 77: 665-676
8 Clarkson AR, MacDonald MK, Cash JD, Robson JS. Modification by drugs of urinary fibrin/fibrinogen degradation products in glomerulonephritis. Br Med J 1972; 3: 255-260
9 Marder VJ, Cruz GO, Schumer BR. Evaluation of a new antifibrinogen-coated latex particle agglutination test in the measurement of serum fibrin degradation products. Thromb Haemostas 1977; 37: 183-191
10 Stachurska J, Latallo Z, Kopeé M. Inhibition of platelet aggregation by dialysable fibrinogen degradation products (FDP). Thromb Diath Haemorrh 1970; 23: 91-98
11 Buczko W, De GaetanoG, Franco R, Donati MB. Biological properties of dialysable peptides derived from plasmin digestion of bovine fibrinogen preparations. Thromb Haemostas 1976; 35: 651-657
12 Takaki A, Ishiguro M, Funatsu M. Anticoagulant peptide obtained from fibrinogen degradation products by plasmin. Proc Japan Acad 1972; 48: 528-533
13 McKenzie R, Pepper DS, Kay AB. The generation of chemotactic activity for human leukocytes by the action of plasmin on human fibrinogen. Thromb Res 1975; 6: 1-8
14 Richardson DL, Pepper DS, Kay AB. Chemotaxis for human monocytes by fibrinogen-derived peptides. Br J Haematol 1976; 32: 507-513
15 Malofiejew M. The biological and pharmacological properties of some fibrinogen degradation products. Scand J Haematol 1971; Suppl. 13: 303-308
16 Solum NO, Rigollot C, Budzyñski AZ, Marder VJ. A quantitative evaluation of the inhibition of platelet aggregation by low molecular weight degradation products of fibrinogen. Br J Haematol 1973; 24: 419-434
17 Mosseson MW, Sherry S. The preparation of properties of human fibrinogen of relatively high solubility. Biochemistry 1966; 5: 2829-2835
18 Marder VJ, James HL, Sherry S. The purification of fibrinogen degradation products by pevikon block electrophoresis. Thromb Diath Haemorrh 1969; 22: 234-239
19 Fairbanks G, Steck TL, Wallach DFH. Electrophoretic analysis of the major polypeptides of the human erythrocyte membrane. Biochemistry 1971; 10: 2606-2617
20 Lowry OH, Rosebrough NJ, Farr AL, Randall RJ. Protein measurement with the Folin phenol reagent. J Biol Chem 1951; 193: 265-275
21 Ward PA, Cochrane CG, Müller-Eberhard HJ. The role of serum complement in chemotaxis of leukocytes in vitro. J Exp Med 1965; 122: 327-346
22 Nitta R, Hayashi H, Norimatsu K. Quantitative extraction of pontamine blue from skin; Its application for measurement of increased capillary permeability. Proc Soc exp Biol Med 1963; 113: 185-187
23 Luft JH. Improvements in epoxy resin embedding methods. J Biophys Biochem Cytol 1961; 9: 409-414
24 Henry RL. Leykocytes and thrombosis. Thromb Diath Haemorrh 1965; 13: 35-46
25 Koga M. Experimental study on resolution and organization of thrombi in pulmonary arteries of rabbits. Fukuoka Igaku Zasshi 1971; 62: 525-540
26 Hisano S, Sueishi K, Ishii Y, Tanaka K. Immunohistochemical and histochemical investigations on in vivo thrombosis with urokinase in rabbits. Thromb Haemostas 1979; 41: 796-803
27 Barnhart MI, Sulisz L, Bluhm GB. Role for fibrinogen and its derivatives in acute inflammation. In Forscher BK, Houck JC. (ed) Immunopathology of Inflammation (Excerpta Medica. International congress series, No 229). Amsterdam: 1971: 59-65
28 Tanaka K. Role of fibrinolysis in various pathological conditions. Tr Soc Path Jap 1977; 66: 03-26
29 Stewart GJ. The intravascular generation of fibrinogen derivatives and the blood vessel wall in venous thrombosis and disseminated intravascular coagulation. Thromb Haemostas 1977; 38: 831-849
30 Barnhart MI. Role of blood coagulation in acute inflammation. In Houck JC, Forscher BK. (ed) Brook Lodge Conference on Inflammation, Augusta, Mich., 1967. Chemical Biology of Inflammation. Pergamon Press; Oxford: 1968: 205-218
31 Stecher VJ, Sorkin E. The chemotactic activity of fibrin lysis products. Int Arch Allergy Appl Immunol 1972; 43: 879-886
32 Wilhelm DL. Increased vascular permeability in acute inflammation. Rev Can Biol 1971; 30: 153-172
33 Wilhelm DL. Inflammation and healing. In Anderson WAD, Kissane JM. (ed) Pathology: Mosby Co, St Louis; 1977: 25-89
34 Majno G, Shea SM, Leventhal M. Endothelial contraction induced by histamine-type mediators. An electron microscopic study. J Cell Biol 1969; 42: 647-672